Markets

Novartis: Pluvicto Shows Effectiveness In Real-world Studies

February 24, 2026 — 08:35 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Novartis (NVS) said multiple US real-world studies reinforced earlier use of Pluvicto before chemotherapy in metastatic castration-resistant prostate cancer. Real-world use of Pluvicto resulted in a median progression-free survival of 13.5 months in chemo-naïve patients with metastatic castration-resistant prostate cancer. Also, real-world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead of multiple ARPIs.

The company said real-world findings are consistent with PSMAfore, which supported the approval of Pluvicto for patients with PSMA-positive mCRPC who have been treated with an ARPI and are considered appropriate to delay taxane-based chemotherapy.

In pre-market trading on NYSE, Novartis shares are up 1.03 percent to $166.40.

For More Such Health News, visit rttnews.com.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
NVS

Latest Articles
Data is currently not available